| Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics IS Vizirianakis, GA Mystridis, K Avgoustakis, DG Fatouros, M Spanakis Oncology Reports 35 (4), 1891-1904, 2016 | 26 | 2016 |
| Thiazole/thiadiazole/benzothiazole based thiazolidin-4-one derivatives as potential inhibitors of main protease of SARS-CoV-2 A Petrou, P Zagaliotis, NF Theodoroula, GA Mystridis, IS Vizirianakis, ... Molecules 27 (7), 2180, 2022 | 25 | 2022 |
| Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics IS Vizirianakis, AN Miliotou, GA Mystridis, EG Andriotis, II Andreadis, ... Expert Review of Precision Medicine and Drug Development 4 (3), 139-151, 2019 | 22 | 2019 |
| Designing an “all-in-one” microextraction capsule device for the liquid chromatographic-fluorescence determination of doxorubicin and its metabolites in rat plasma G Mamounas, N Manousi, A Kabir, KG Furton, GA Mystridis, ... Journal of Chromatography A 1680, 463432, 2022 | 10 | 2022 |
| Artificial Intelligence/Machine Learning and mechanistic modeling approaches as translational tools to advance personalized medicine decisions GA Mystridis, F Chatzopoulou, GP Patrinos, IS Vizirianakis Advances in Molecular Pathology 5 (1), 131-139, 2022 | 7 | 2022 |
| Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling P Zagaliotis, A Petrou, GA Mystridis, A Geronikaki, IS Vizirianakis, ... International Journal of Molecular Sciences 23 (14), 8006, 2022 | 5 | 2022 |
| Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin GA Mystridis, GC Batzias, IS Vizirianakis Pharmaceutics 14 (3), 541, 2022 | 4 | 2022 |
